PT - JOURNAL ARTICLE AU - Nanishi, Etsuro AU - Levy, Ofer AU - Ozonoff, Al TI - Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review AID - 10.1101/2022.01.15.22269364 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.15.22269364 4099 - http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269364.short 4100 - http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269364.full AB - The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 04 November 2021 that provide effectiveness data on mRNA vaccines approved/licensed in the United States and identified eight eligible studies which evaluated vaccine effectiveness in older adults. There is evidence of a decline in vaccine effectiveness against both SARS-CoV-2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that vaccine effectiveness diminishes in older adults, which supports the current recommendation for a booster dose in this population.Competing Interest StatementOL is a part time employee of the U.S. FDA and a named inventor on patents relating to vaccine adjuvants and human in vitro models that model vaccine action.Funding StatementThis study is funded by in part via NIH/NIAID NIH/NIAID grants and contracts including Adjuvant Discovery (HHSN272201400052C and 75N93019C00044) and Development (HHSN272201800047C) Program Contracts as well as the Boston Children's Hospital Department of Pediatrics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study reviewed 8 peer-reviewed publication available in PubMed. Descriptions of the included papers are stated in the paper.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.